Drug intelligence / Profile preview

pamiparib + tislelizumab

Development stage: Unknown
Lead developer: BeiGene
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

Pamiparib + tislelizumab is a combination therapy consisting of pamiparib, an oral poly (ADP-ribose) polymerase (PARP) 1/2 inhibitor, and tislelizumab, a humanized anti-PD-1 monoclonal antibody. This combination has been studied in patients with advanced solid tumors and has shown antitumor responses and clinical benefit. The recommended phase 2 dose is tislelizumab 200 mg intravenously every 3 weeks plus pamiparib 40 mg orally twice daily.

Brand names: No unique brand name for the combinationBaizeanNo widely recognized brand name
Other names: No widely used other names for this combination

Targets

PDCD1 (Programmed cell death protein 1 receptor)PARP2 (Poly (adp-ribose) polymerase 2)

Beyond the preview

Go deeper on pamiparib + tislelizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on pamiparib + tislelizumab.

Explore the full profile